Karam Mounzer Selected Research

Karam Mounzer Research Topics

Disease

9	HIV Infections (HIV Infection) 01/2023 - 07/2013
8	Infections 10/2022 - 12/2004
6	Viremia 01/2022 - 03/2010
5	Inflammation (Inflammations) 01/2023 - 09/2020
2	Weight Gain 10/2022 - 11/2021
2	Acquired Immunodeficiency Syndrome (AIDS) 01/2022 - 01/2019
2	Substance-Related Disorders (Drug Abuse) 01/2020 - 01/2015
2	Coinfection 01/2020 - 01/2020
2	Tobacco Use Disorder (Nicotine Dependence) 01/2019 - 01/2019
1	Thrombocytopenia (Thrombopenia) 01/2023
1	Pneumonia (Pneumonitis) 01/2023
1	COVID-19 01/2023
1	Opioid-Related Disorders (Opiate Addiction) 10/2022
1	Obesity 11/2021
1	Prediabetic State (Prediabetes) 01/2021
1	Type 2 Diabetes Mellitus (MODY) 01/2021
1	Neoplasms (Cancer) 01/2021
1	Shock 10/2020
1	Hypersensitivity (Allergy) 01/2019
1	Angioedema 02/2016
1	Mental Disorders (Mental Disorder) 01/2015
1	Hepatitis C 07/2014
1	Colorectal Neoplasms (Colorectal Cancer) 01/2014
1	Herpes Zoster 04/2013
1	Dizziness (Lightheadedness) 02/2010
1	Thromboembolism 09/2008
1	Disease Progression 09/2008
1	Cardiovascular Diseases (Cardiovascular Disease) 06/2008
1	Weight Loss (Weight Reduction) 03/2007
1	Body Weight (Weight, Body) 03/2007
1	Opportunistic Infections (Opportunistic Infection) 02/2006

Drug/Important Bio-Agent (IBA)

4	Immunoglobulin G (IgG)IBA 10/2022 - 01/2018
4	Polysaccharides (Glycans)IBA 10/2022 - 01/2018
4	RNA (Ribonucleic Acid)IBA 01/2022 - 07/2014
3	dolutegravirIBA 01/2023 - 01/2021
3	Darunavir (Prezista)FDA Link 01/2023 - 01/2021
3	elvitegravirIBA 01/2023 - 01/2021
3	CytokinesIBA 10/2022 - 09/2008
3	InterferonsIBA 09/2020 - 03/2007
3	Ribavirin (Virazole)FDA LinkGeneric 01/2020 - 03/2007
2	drug combination tenofovir alafenamide emtricitabine bictegravirIBA 01/2023 - 03/2022
2	RacivirIBA 10/2022 - 02/2010
2	CobicistatIBA 03/2022 - 01/2021
2	Antiviral Agents (Antivirals)IBA 09/2020 - 01/2020
2	DNA (Deoxyribonucleic Acid)IBA 09/2020 - 01/2018
2	VaccinesIBA 02/2016 - 04/2013
2	Interferon-alpha (Interferon Alfa)IBA 07/2013 - 03/2010
2	NucleosidesIBA 05/2011 - 03/2007
1	Meropenem (Merrem)FDA LinkGeneric 01/2023
1	Broadly Neutralizing AntibodiesIBA 01/2023
1	Monoclonal AntibodiesIBA 01/2023
1	Viral AntigensIBA 01/2023
1	Opioid Analgesics (Opioids)IBA 10/2022
1	Lipopolysaccharide ReceptorsIBA 10/2022
1	Emtricitabine (Emtriva)FDA Link 10/2022
1	tenofovir alafenamideIBA 10/2022
1	Anti-Retroviral Agents (Antiretroviral Agents)IBA 10/2022
1	imidazole mustard (BIC)IBA 10/2022
1	Methadone (Dolophine)FDA LinkGeneric 10/2022
1	Naltrexone (ReVia)FDA LinkGeneric 10/2022
1	Integrase InhibitorsIBA 03/2022
1	AntigensIBA 01/2022
1	gniditrinIBA 01/2022
1	YuanhuacinIBA 01/2022
1	YuanhuajineIBA 01/2022
1	mezereinIBA 01/2022
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2022
1	Raltegravir Potassium FDA Link 01/2021
1	LipidsIBA 01/2021
1	LysophospholipidsIBA 01/2021
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	abacavir (Ziagen)FDA Link 01/2019
1	efavirenz (Sustiva)FDA Link 01/2019
1	Varenicline (Chantix)FDA Link 01/2019
1	SmokeIBA 01/2019
1	Carbon MonoxideIBA 01/2019
1	Nicotine FDA Link 01/2019
1	HLA-B57 antigenIBA 01/2019
1	SofosbuvirIBA 07/2014
1	Calcibiotic Root Canal SealerIBA 01/2014
1	Retinoblastoma ProteinIBA 08/2012
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2012
1	Protein Isoforms (Isoforms)IBA 09/2010
1	ZincIBA 09/2010
1	MetallothioneinIBA 09/2010
1	TNF-Related Apoptosis-Inducing LigandIBA 03/2010
1	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 03/2010
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2010
1	AnticoagulantsIBA 09/2008
1	Reverse Transcriptase InhibitorsIBA 03/2007
1	Testosterone (Sustanon)FDA Link 02/2006
1	Tuberculin (PPD)IBA 10/2005

Therapy/Procedure

9	Therapeutics 01/2022 - 12/2004
5	Art Therapy 01/2023 - 01/2020
3	Highly Active Antiretroviral Therapy (HAART) 01/2023 - 02/2006
1	Catheters 01/2023
1	Length of Stay 01/2023
1	Central Venous Catheters 01/2023
1	Retention in Care 01/2015